PS1 stabilizes the cadherin/catenin complex. (A)
Extracts of confluent E-cadherin-transfected PS1+/+ and PS1−/−
fibroblasts in 1% Triton X-100 were treated with anti-E-cadherin
antibody, and the resulting IPs (E-cad IP, Right), along
with total cell lysate in 1% SDS (Left), were probed on
WBs with antibodies against the proteins indicated at the right of the
figure. The asterisk denotes low-molecular-weight IgGs.
(B) Anti-β-catenin, anti-γ-catenin, or
anti-α-catenin IPs (Top, Middle, and
Bottom, respectively) prepared from
E-cadherin-expressing PS1+/+ and PS1−/− fibroblasts were probed
with anti-E-cadherin (E-cad), anti-β-catenin (β-cat),
anti-γ-catenin (γ-cat), or anti-α-catenin (α-cat) antibodies.
(C and D) Extracts (1% Triton X-100) of
E-cadherin-expressing PS1−/− fibroblasts transiently transfected
with vector (VECT), WT PS1 (wtPS1), or PS1 FAD mutant ΔE9 (PS1ΔE9)
were treated with anti-E-cadherin (E-cad IP), anti-β-catenin (β-cat
IP) (C), or anti-γ-catenin (γ-cat IP)
(D) antibodies, and the resulting IPs were probed with
antibodies against the proteins indicated at the right of the figure.
E-cad, E-cadherin; β-cat, β-catenin; γ-cat, γ-catenin.